Daré Bioscience, Inc

(NASDAQ:DARE)

Latest On Daré Bioscience, Inc (DARE):

Date/Time Type Description Signal Details
2023-05-12 08:19 ESTNewsDaré Bioscience, Inc. (DARE) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 18:46 ESTNewsDare Bioscience GAAP EPS of -$0.09 beats by $0.01N/A
2023-05-11 18:46 ESTNewsDare Bioscience GAAP EPS of -$0.09N/A
2023-05-11 03:52 ESTNewsDare Bioscience Q1 2023 Earnings PreviewN/A
2023-03-31 03:39 ESTNewsDare Bioscience GAAP EPS of -$0.37 misses by $0.07, revenue of $10M in-lineN/A
2023-03-31 03:39 ESTNewsDare Bioscience, Inc. (DARE) Q4 2022 Earnings Call TranscriptN/A
2023-03-30 02:57 ESTNewsDare Bioscience FY 2022 Earnings PreviewN/A
2023-01-25 15:46 ESTNewsDaré Bioscience hits seven-month high after regaining listing complianceN/A
2022-11-15 17:47 ESTNewsDaré gets Gates Foundation grant to develop Hydrogel tech for use in vaginal healthN/A
2022-11-11 08:38 ESTNewsDare Bioscience, Inc. (DARE) Q3 2022 Earnings Call TranscriptN/A
2022-11-11 08:38 ESTNewsDaré Bioscience, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-10 15:39 ESTNewsDare Bioscience GAAP EPS of -$0.08 beats by $0.03N/A
2022-11-09 22:54 ESTNewsDare Bioscience Q3 2022 Earnings PreviewN/A
2022-10-17 14:03 ESTNewsDaré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptomsN/A
2022-10-10 11:17 ESTNewsDaré Bioscience rises as company submits application to begin trial of non-hormonal contraceptiveN/A
2022-08-30 03:26 ESTNewsDare Bioscience reports positive progress for cream for female sexual arousal disorderN/A
2022-08-09 22:41 ESTNewsDare Bioscience GAAP EPS of $0.00, revenue of $10MN/A
2022-08-09 22:39 ESTNewsDare Bioscience, Inc. (DARE) CEO Sabrina Johnson on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 22:39 ESTNewsDaré Bioscience, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 01:12 ESTNewsDare Bioscience Q2 2022 Earnings PreviewN/A
2022-07-01 03:31 ESTNewsDaré Bioscience signs agreement with Organon for bacterial vaginosis therapyN/A
2022-05-13 10:48 ESTNewsDare Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 16:11 ESTNewsDare Bioscience GAAP EPS of -$0.10 beats by $0.04N/A
2022-05-11 22:02 ESTNewsDare Bioscience Q1 2022 Earnings PreviewN/A
2022-04-13 01:44 ESTNewsDaré Bioscience begins phase 1/2 trial of DARE-HRT1 for symptoms of menopauseN/A
2022-04-01 05:08 ESTNewsDaré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-31 09:25 ESTNewsDare Bioscience FY 2021 Earnings PreviewN/A
2022-03-31 09:25 ESTNewsOrganon in pact with Daré Bioscience for XaciatoN/A
2022-03-31 09:25 ESTNewsDare Bioscience GAAP EPS of -$0.63 misses by $0.03N/A
2022-02-17 15:12 ESTNewsDaré Bioscience (DARE) Investor Presentation - SlideshowN/A
2022-01-07 19:56 ESTNewsDiving Back Into Daré Bioscience AgainN/A
2021-12-11 08:52 ESTNewsDare Bioscience gives back most of its strong gains from Tuesday's FDA approvalN/A
2021-12-08 05:03 ESTNewsDaré Bioscience wins FDA approval for XACIATO antibacterial gel (updated)N/A
2021-11-12 00:21 ESTNewsDaré Bioscience, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-11 04:31 ESTNewsDaré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-10 06:11 ESTNewsDare Bioscience Q3 2021 Earnings PreviewN/A
2021-10-12 23:29 ESTNewsWarning: DARE is at high risk of performing badlyN/A
2021-10-07 08:29 ESTNewsDARE is at high risk of performing badlyN/A
2021-09-27 16:04 ESTNewsWarning: DARE has been downgraded to Very BearishN/A
2021-09-27 15:58 ESTNewsDaré Bioscience gets NIH grant to support development of DARE-LARC1N/A
2021-09-24 02:39 ESTNewsDaré Bio launches Phase 1/2 study of DARE-VVA1 for vulvar and vaginal atrophyN/A
2021-09-21 16:05 ESTNewsWarning: DARE has been downgraded to Very Bearish.N/A
2021-08-16 16:24 ESTNewsDaré Bioscience, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-13 11:58 ESTNewsDaré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-12 15:34 ESTNewsDare Bioscience EPS misses by $0.02N/A
2021-08-10 02:12 ESTNewsDaré Bioscience shares surge 13% on FDA priority review status for DARE-BV1 NDAN/A
2021-07-21 04:02 ESTNewsDaré Bioscience shares rise after early-stage DARE-HRT1 study resultsN/A
2021-07-21 03:58 ESTNewsDaré Bioscience reaches over three-month high as Roth boosts price targetN/A
2021-07-21 03:51 ESTNewsDaré Bioscience soars on grant from Gates FoundationN/A
2021-07-21 03:45 ESTNewsDaré Bio inks research deal for Phase 3 study of contraceptive OvapreneN/A

About Daré Bioscience, Inc (DARE):

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company intends to develop therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application that completed Phase 3 clinical trials; Ovaprene, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214 injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is based in San Diego, California.

DARE Quotes by TradingView

See Advanced Chart

General

  • Name Daré Bioscience, Inc
  • Symbol DARE
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 15
  • Last Split Factor1:10
  • Last Split Date2017-07-20
  • Fiscal Year EndDecember
  • IPO Date2014-04-10
  • Gic SectorHealth Care
  • Gic GroupHealth Care Equipment & Services
  • Gic IndustryHealth Care Equipment & Supplies
  • Gic SubIndustryHealth Care Supplies
  • Web URLhttp://www.darebioscience.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 131.82
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.14
  • Return on Assets -247%
  • Return on Equity -10764%
  • Earnings Per Share -$1.05
  • Revenue Per Share $0
  • Gross Profit -533334
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 82.78 million
  • EBITDA -13093210
  • Analyst Target Price $5.2
  • Book Value Per Share $0.02
View More

Share Statistics

  • Shares Outstanding 41.6 million
  • Shares Float 35.47 million
  • % Held by Insiders 830%
  • % Held by Institutions 5.89%
  • Shares Short 1.2 million
  • Shares Short Prior Month 1.43 million
  • Short Ratio 0.65
  • Short % of Float 3%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.58
  • 52 Week High $3.01
  • 52 Week Low $0.78
  • 50 Day Moving Average 2.15
  • 200 Day Moving Average 1.48
View More

Dividends

  • Dividend Date 2017-07-20
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Daré Bioscience, Inc (DARE) Dividend Calendar:

DARE's last dividend payment was made to shareholders on July 20, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Daré Bioscience, Inc (DARE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-12$N/A-$0.24-$0.19-29.73%
2020-06-302020-08-12$N/A-$0.27-$0.17-61.97%
2020-03-312020-05-14$N/A-$0.18-$0.3344.9%
2019-12-312020-03-27$N/A-$0.21-$0.20-7.69%
2019-09-302019-11-12$N/A-$0.20-$0.201.23%
2019-06-302019-08-14$N/A-$0.29-$0.20-47.43%
2019-03-312019-05-14$N/A-$0.27-$0.3010%
2018-12-312018-12-31$N/A-$0.25-$0.277.41%
2018-09-302018-11-13$N/A-$0.23-$0.256.77%
2018-06-302018-08-13$N/A-$0.32-$0.24-36.17%
2018-03-312018-05-14$N/A-$0.88
2017-12-312018-03-28$1.83 million-$1.51-$3.1051.29%
2017-09-302017-11-13$-2476000-$0.33
2017-06-302017-08-14$642000-$1.42
2017-03-312017-05-12$1.19 million-$2.70-$3.1012.9%
2016-12-312017-03-31$766000-$1.60-$3.3552.24%
2016-09-302016-11-03$N/A-$3.60-$4.0811.76%
2016-06-302016-08-04$N/A-$4.00-$4.8116.84%
2016-03-312016-05-02$N/A-$4.90-$0.43-1039.53%
2015-12-312016-03-10$N/A-$3.90-$0.41-851.22%
2015-09-302015-11-16$N/A-$0.39-$0.414.88%
2015-06-302015-08-06$N/A-$0.37-$0.4211.9%
2015-03-312015-05-06$N/A-$0.41-$0.4814.58%
2014-12-312015-03-19$80000-$0.34-$0.4930.61%
2014-09-302014-11-13$1.64 million-$0.28-$0.4030%
2014-06-302014-08-12$33000-$2.90-$3.6019.44%
2014-03-312014-05-27$47000-$37.00-$2.97-1145.79%

Daré Bioscience, Inc (DARE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development 6.2 million 5.55 million 2.38 million N/A 1.97 million
Income Before Tax -7.58 million -7.12 million -4.25 million N/A -3.39 million
Selling General Administrative 1.38 million 1.58 million 1.87 million N/A 1.32 million
Gross Profit N/A N/A N/A N/A -133333
Ebit -7.57 million -7.11 million -4.24 million N/A -3.42 million
Operating Income -7.58 million -7.13 million -4.25 million N/A -3.42 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A 133333
Total Other Income Expense Net -986 1618 1821 N/A 25471
Net Income From Continuing Operations -7.58 million -7.12 million -4.25 million N/A -3.39 million
Net Income Applicable to Common Shares -7.59 million N/A -4.25 million -3.08 million -3.39 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities N/A N/A N/A 478004 -279876
Total Cash Flow from Investing Activities N/A N/A N/A 6.14 million N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 5.4 million 4.39 million 6.89 million N/A N/A
Change to Operating Activities N/A N/A N/A -347119 -98867
Change in Cash 42542 299547 267218 N/A -3.2 million
Total Cash from Operating Activities -5.36 million -4.09 million -6.6 million -3.81 million -3.18 million
Depreciation 12499 11980 11949 N/A 1176
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A 455180
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A N/A N/A -124239 135393
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities 9.05 million 8.26 million 7 million N/A 2.07 million
Total Stockholder Equity -1.39 million 311255 3.21 million N/A 1.81 million
Other Current Liabilities 1000000 N/A N/A N/A N/A
Total Assets 7.66 million 8.57 million 10.21 million N/A 3.88 million
Common Stock N/A N/A N/A 1968 1668
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -62.99 million -55.4 million -48.28 million -44.02 million -40.16 million
Other Liabilities N/A N/A N/A 1000000 183196
Other Assets N/A N/A N/A 935325 632648
Cash 5.39 million 5.35 million 5.05 million N/A 2.44 million
Total Current Liabilities 7.96 million 6.08 million 4.72 million N/A 1.89 million
Other Stockholder Equity N/A N/A N/A -102625 -112402
Property, Plant & Equipment N/A N/A N/A 63531 5905
Total Current Assets 6.98 million 7.78 million 9.32 million N/A 3.24 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets N/A N/A N/A 440826 1.81 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.56 million 1.71 million 1.53 million N/A 352243

Daré Bioscience, Inc (DARE) Chart:

Daré Bioscience, Inc (DARE) News:

Below you will find a list of latest news for Daré Bioscience, Inc (DARE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Daré Bioscience, Inc (DARE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest DARE Trades:

Date Shares Price
Jun 13, 2022 5:59 PM EST1$1.24
Jun 13, 2022 6:20 PM EST5$1.24
Jun 13, 2022 7:10 PM EST100$1.225
Jun 13, 2022 7:21 PM EST100$1.21
Jun 13, 2022 7:32 PM EST100$1.21

Daré Bioscience, Inc (DARE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000098/0001401914-20-000098-index.htm
2018-09-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1401914/000000000018027798/0000000000-18-027798-index.htm
2020-05-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1401914/000000000020004042/0000000000-20-004042-index.htm
2020-05-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1401914/000000000020004649/0000000000-20-004649-index.htm
2019-01-15SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1401914/000090266419000189/0000902664-19-000189-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1401914/000110465919008594/0001104659-19-008594-index.htm
2018-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518216324/0001193125-18-216324-index.htm
2018-08-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1401914/000119312518251659/0001193125-18-251659-index.htm
2018-08-24S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1401914/000119312518257805/0001193125-18-257805-index.htm
2018-08-24S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1401914/000119312518257813/0001193125-18-257813-index.htm
2018-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518258165/0001193125-18-258165-index.htm
2018-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518266651/0001193125-18-266651-index.htm
2018-09-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1401914/000119312518270115/0001193125-18-270115-index.htm
2018-09-10S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1401914/000119312518270122/0001193125-18-270122-index.htm
2018-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518275237/0001193125-18-275237-index.htm
2018-09-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1401914/000119312518278347/0001193125-18-278347-index.htm
2018-09-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1401914/000119312518278351/0001193125-18-278351-index.htm
2018-09-25424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1401914/000119312518282604/0001193125-18-282604-index.htm
2018-09-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000119312518283920/0001193125-18-283920-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518324817/0001193125-18-324817-index.htm
2018-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518335165/0001193125-18-335165-index.htm
2018-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518338016/0001193125-18-338016-index.htm
2018-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518343676/0001193125-18-343676-index.htm
2018-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000119312518346148/0001193125-18-346148-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000119312519039141/0001193125-19-039141-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000119312519039148/0001193125-19-039148-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000119312519040784/0001193125-19-040784-index.htm
2020-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1401914/000119312520033343/0001193125-20-033343-index.htm
2019-04-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000119910219000004/0001199102-19-000004-index.htm
2018-07-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919118042385/0001209191-18-042385-index.htm
2018-07-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919118042386/0001209191-18-042386-index.htm
2018-07-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919118042387/0001209191-18-042387-index.htm
2018-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919118050350/0001209191-18-050350-index.htm
2018-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919118050351/0001209191-18-050351-index.htm
2018-09-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919118051266/0001209191-18-051266-index.htm
2018-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919118051267/0001209191-18-051267-index.htm
2019-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919119006215/0001209191-19-006215-index.htm
2019-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000120919119006217/0001209191-19-006217-index.htm
2019-04-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000125738619000003/0001257386-19-000003-index.htm
2019-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000125738619000005/0001257386-19-000005-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000125738619000007/0001257386-19-000007-index.htm
2019-02-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1401914/000139382519000053/0001393825-19-000053-index.htm
2019-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000003/0001401914-19-000003-index.htm
2019-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000006/0001401914-19-000006-index.htm
2019-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000008/0001401914-19-000008-index.htm
2019-04-0110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1401914/000140191419000015/0001401914-19-000015-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000017/0001401914-19-000017-index.htm
2019-04-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000140191419000020/0001401914-19-000020-index.htm
2019-04-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000023/0001401914-19-000023-index.htm
2019-04-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000140191419000025/0001401914-19-000025-index.htm
2019-04-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000027/0001401914-19-000027-index.htm
2019-04-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000029/0001401914-19-000029-index.htm
2019-04-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000032/0001401914-19-000032-index.htm
2019-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000034/0001401914-19-000034-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000038/0001401914-19-000038-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000039/0001401914-19-000039-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000047/0001401914-19-000047-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401914/000140191419000048/0001401914-19-000048-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000050/0001401914-19-000050-index.htm
2019-05-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000140191419000055/0001401914-19-000055-index.htm
2019-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000058/0001401914-19-000058-index.htm
2019-06-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000060/0001401914-19-000060-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000062/0001401914-19-000062-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000064/0001401914-19-000064-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000066/0001401914-19-000066-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000068/0001401914-19-000068-index.htm
2019-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000071/0001401914-19-000071-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000074/0001401914-19-000074-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000080/0001401914-19-000080-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401914/000140191419000081/0001401914-19-000081-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000084/0001401914-19-000084-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000086/0001401914-19-000086-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000088/0001401914-19-000088-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401914/000140191419000090/0001401914-19-000090-index.htm
2019-11-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000097/0001401914-19-000097-index.htm
2019-11-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000099/0001401914-19-000099-index.htm
2019-11-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000100/0001401914-19-000100-index.htm
2019-11-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000102/0001401914-19-000102-index.htm
2019-12-06DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000103/0001401914-19-000103-index.htm
2019-12-09SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000106/0001401914-19-000106-index.htm
2019-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191419000109/0001401914-19-000109-index.htm
2020-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000003/0001401914-20-000003-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000007/0001401914-20-000007-index.htm
2020-01-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000009/0001401914-20-000009-index.htm
2020-01-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000012/0001401914-20-000012-index.htm
2020-01-308-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000014/0001401914-20-000014-index.htm
2020-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000018/0001401914-20-000018-index.htm
2020-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000020/0001401914-20-000020-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000022/0001401914-20-000022-index.htm
2020-02-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000024/0001401914-20-000024-index.htm
2020-02-21SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000026/0001401914-20-000026-index.htm
2020-03-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000028/0001401914-20-000028-index.htm
2020-03-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000032/0001401914-20-000032-index.htm
2020-03-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000034/0001401914-20-000034-index.htm
2020-03-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000036/0001401914-20-000036-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000038/0001401914-20-000038-index.htm
2020-03-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/0001401914-20-000042-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000044/0001401914-20-000044-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000048/0001401914-20-000048-index.htm
2020-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000050/0001401914-20-000050-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000052/0001401914-20-000052-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000054/0001401914-20-000054-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000056/0001401914-20-000056-index.htm
2020-05-01S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1401914/000140191420000060/0001401914-20-000060-index.htm
2020-05-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000062/0001401914-20-000062-index.htm
2020-05-12424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000065/0001401914-20-000065-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000068/0001401914-20-000068-index.htm
2020-05-15S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1401914/000140191420000071/0001401914-20-000071-index.htm
2020-05-20424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000073/0001401914-20-000073-index.htm
2020-05-29CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000075/0001401914-20-000075-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000077/0001401914-20-000077-index.htm
2020-06-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000079/0001401914-20-000079-index.htm
2020-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000081/0001401914-20-000081-index.htm
2020-06-08424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000083/0001401914-20-000083-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000085/0001401914-20-000085-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000093/0001401914-20-000093-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000094/0001401914-20-000094-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000095/0001401914-20-000095-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000096/0001401914-20-000096-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000097/0001401914-20-000097-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000098/0001401914-20-000098-index.htm
2020-07-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000100/0001401914-20-000100-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000105/0001401914-20-000105-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000109/0001401914-20-000109-index.htm
2020-09-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1401914/000140191420000111/0001401914-20-000111-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000140191420000114/0001401914-20-000114-index.htm
2020-04-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000149315220005629/0001493152-20-005629-index.htm
2019-04-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000151124119000003/0001511241-19-000003-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000153657419000001/0001536574-19-000001-index.htm
2018-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/0001564590-18-021487-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1401914/000156459018029135/0001564590-18-029135-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000156459019000281/0001564590-19-000281-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1401914/000162828019008388/0001628280-19-008388-index.htm
2019-04-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1401914/000171157619000003/0001711576-19-000003-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1401914/000173678119000001/0001736781-19-000001-index.htm
2018-09-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1401914/999999999518002432/9999999995-18-002432-index.htm
2018-09-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1401914/999999999518002433/9999999995-18-002433-index.htm
2020-05-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1401914/999999999520001128/9999999995-20-001128-index.htm
2020-06-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1401914/999999999520001366/9999999995-20-001366-index.htm
2018-08-30CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1401914/999999999718007532/9999999997-18-007532-index.htm
2019-04-11CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1401914/999999999719002774/9999999997-19-002774-index.htm
2020-02-10SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1401914/999999999720000615/9999999997-20-000615-index.htm
2020-03-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1401914/999999999720001151/9999999997-20-001151-index.htm

Daré Bioscience, Inc (DARE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Daré Bioscience, Inc (DARE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 830%
Institutional Ownership: 589%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-04-11ROGER HAWLEYDirectorBuy454,545.001.10499,999.50944,956.00https://www.sec.gov/Archives/edgar/data/1401914/000125738619000005/0001257386-19-000005-index.htm